Last updated on November 2018

A Single-dose Study in Paediatric Subjects Aged 2 to Less Than 18 Years With (sHPT) Receiving Haemodialysis

Brief description of study

This is a multicenter, open-label study to evaluate the safety and pharmacokinetics in pediatric subjects with secondary hyperparathyroidism receiving a single dose of AMG 416 at the end of hemodialysis.

Detailed Study Description

A Single-dose Study to Evaluate the Safety and Pharmacokinetics in Paediatric Subjects Aged 2 to less than 18 Years with (sHPT) Receiving Maintenance Haemodialysis

Clinical Study Identifier: NCT02833857

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Krakow, Poland